As some pretty costly, yet very useful, drugs are introduced, will new formulary designs deny access to needy patients?
A growing number of health plans are adding these clinics in retail stores to their networks and are realizing savings
An exercise in "point-counterpoint" at a recent disease management meeting showed dramatic swings in views
Prepared by the NMHCC Workgroup on Outcomes Assessment in Disease Management
Health plans find themselves paying for the latest and greatest stent without any control over usage. Even bare-metal stents may be overused.
Changing the process and mindset of health care professionals was the key to reducing emergency department overcrowding
Joseph R. Twanmoh, MD, FACEP
Gail P. Cunningham, MD, FACEP
Legislation & Regulation
Patient advocacy groups work overtime to kill legislation that businesses felt would have provided less costly coverage for their employees
Despite the higher costs of SSRIs, compared to older antidepressants, limiting members' access can lead to undertreated depression
The Formulary Files
Imagine an America where few businesses purchase health care for employees. Should that come about, the individual market will have new products ready.
Although Myozyme is approved for the infantile form of Pompe disease, it is logical to extend coverage to patients with the late onset form
Thomas Morrow, MD
Managed Care Outlook